A retrospective study comparing efficacy and safety of subcutaneous alemtuzumab and intravenous alemtuzumab in graft-versus-host disease (GVHD) prophylaxis for matched unrelated donor stem cell transplantations
Latest Information Update: 16 Dec 2016
At a glance
- Drugs Alemtuzumab (Primary) ; Alemtuzumab (Primary) ; Fludarabine; Melphalan; Tacrolimus
- Indications Graft-versus-host disease
- Focus Adverse reactions; Therapeutic Use
- 16 Dec 2016 New trial record